Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Roth Capital presentation (October 2009)
19 slides from Lisata Therapeutics's conference presentation, Oct 13, 2009
Slide 1: NeoStem, Inc. Presentation for Roth Capital
Exhibit 99.1 NeoStem, Inc. (“NBS”) Presentation for Roth Capital October 14, 2009 6°. NeeStem —
Slide 2: Forward-looking statements
Certain statements in this presentation constitute “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements relating to NeoStem, inc. (the “Company” or "NBS') in general as well as with respect to the Company's propo
Slide 3: NeoStem Today
— NeoStem Today « — Listed on the NYSE AMEX (ticker: NBS) = Completed approximately $32 million in financing through June 2009 = Leading operator of commercial autologous adult stem cell bank + Pioneering pre-disease collection, processing and long-term storage of stem cells from adult donors for th
Slide 4: Post Transaction
— Post Transaction NeoStem, Inc. (NYSE Amex: NBS) Stem Cell Banking [i Stem Cell Therapy Stem Cell R&D ebletat OtheRConmenssa) Therapy Drugs Activities NeeStem —
Slide 5: Post Transaction
— Post Transaction Uniting three strong entities with multi-disciplinary expertise to tap high-growth opportunities in China and the US quickly and efficiently (1) (2) (3) NeoStem, US Leading stem storage company in US Exclusive worldwide license to innovative VSEL™ Technology which drives young ste
Slide 6: Stem Cell Businesses
— Stem Cell Businesses R&D focused on = Leading operator of commercial collection and stem cell bank in US proprietary VSEL + Minimally invasive extraction procedure (“apheresis”) technology with a + Pioneering pre-disease collection, processing and long-term storage of stem cells view towards the f
Slide 7: Virtually All Therapeutic Areas
— Virtually All Therapeutic Areas Over 2,600 adult = By 2017, it is forecast that a minimum of 16 stem cell products will be stem cell clinical approved through the FDA and used in 1.9 million procedures annually” trials + Autoimmune + Diabetes/Metabolic Forecast to bea + Cardiovascular US$20 billio
Slide 8: VSEL Technology
— VSEL™ Technology Very Small = Each person has a population of primitive, embryonic-like stem cells that Embryonic-Like have remained since birth stem cells are + May retain characteristics typically found in embryonic stem cells among the most + Can be mobilized in the blood and extracted using ap
Slide 9: Comparables
— Comparables ‘Comps Analysis -Neostem ‘Share Price MitCap eS pe Name exchange County industry (uso) _(wmusp) 2010 et me Neostem Amex Usa stemealls 205 09 as Ne nM rd Blood America or usa Stem ells 2.00 836 (coy nM nM ryo-Calnt ore ry Stem Cells 225 25.44 (0.05) NM NM Viacel (purchased by Pt} stem c
Slide 10: Suzhou Erye Pharmaceutical
— Suzhou Erye Pharmaceutical China provides a « Vertically-integrated biopharmaceutical company that develops, manufactures strong financial and distributes innovative drugs in China underpinning to + NBS is acquiring 51% of Suzhou Erye; anticipated closing by end of October the Group and + Strong p
Slide 11: Suzhou Erye Pharmaceutical
— Suzhou Erye Pharmaceutical Suzhou Erye is = China’s pharmaceutical market is large and growing* well-positioned to + Annual drug bill $73 billion, nearly double the international average continue its rapid + National pharmaceutical market to grow from $24.5 billion currently to $78 billion in grow
Slide 12: Suzhou Erye Pharmaceutical comps analysis
— Suzhou Erye Pharmaceutical Comps Analysis - Suzhou Erye Pharmaceutical Share Price MktCap EPS PE Name Exchange Country __Industry (usb) __(MMUSD)_Latesta “LatestQ__2010 Mingsheng Investment Management Co.,Inc. Shenzhen China Pharmaceuticals 130 6899 0.02 BS NM S&P Pharmaceutical Industry Shanghai
Slide 13: Proposed Combined Company - Revenue Sources
— Proposed Combined Company - Revenue Sources CBH's Pharma NeoStem, Inc. revenues and {NYSE Amex: earnings provide NBS) certain stability that should be able to underpin the Sees Stem Cell Stem Cell Traditional sen Stem Cell R&D Commercial Banking Therapy Therapy Drugs NBS brings Activities innovati
Slide 14: Post-Merger Management
— Post-Merger Management + Medical degree, Yale; MBA Wharton * Previous positions include President & CEO 1P2M (healthcare multimedia), EVP & CMO HealthHelp, Inc (radiology management) * Senior advisor & investor to several publicly-traded and private companies with extensive restructuring and growt
Slide 15: Current Advisory Board Members
— Current Advisory Board Members Wayne A Marasco, M.D., PhD ~ Chairman of Scientific Advisory Board ‘Associate Professor, Dept of Cancer and Immunology & AIDS at Dana-Farber Cancer Institute; Associate Prof of Medicine at Harvard Medical School + Leading NBS’ efforts in expanding academic relationsh
Slide 16: Post-Merger Board of Directors
— Post-Merger Board of Directors Robin L Smith, M.D., MBA — Chief Executive Officer and Chairman of the Board Diverse board with +See Post-Merger Management US and Asia Eric HC Wel- Managing Partner, RimAsia Capital Partners, L.P. experience in + Founder and Managing Partner of RimAsia Capital Partn
Slide 17: Post-Merger Capitalization
Post-Merger Capitalization Common Stock (authorized 500 million shares) Warrants Outstanding Series E Warrants Us Stock Options Outstanding Non US Stock Options Outstanding Series C convertible preferred stock {authorized 8,177,512 shares) 36,402,863 Average Exercise Price® $ $ $ $ 2.80 6.55 2.35 1.
Slide 18: Summary
— Summary = Strategic Alliances: Today's revenues from collection, processing & storage are strategic alliances « Focused Acquisition Strategy: Focused on acquiring licensing technology and R&D of therapies to provide value for the future «China Expansion: Move will allow a profitable traditional th
Slide 19: Contact Information
— Contact Information Robin Smith, MD MBA Chairman & CEO Direct: (212) 584-4174 Email: rsmith@neostem.com NeoStem, Inc. 420 Lexington Avenue Suite 450 New York, NY 10170 Main: (212) 584-4180 Fax: (646) 514-7787 www.neostem.com 1.888.STEM BANK 6°. NeeStem —